Drug Establishment License & GMP Manufacturing
Owner, Operator of Two 10,000 Sq. Ft Production Facilities
Global Export for MDMA & Psilocybin Capsules
Backed by +CA$30M in Strategic Funding
As seen on
Optimi can produce GMP MDMA & Psilocybin capsules at a low cost and at scale to ensure their drugs are the most competitively priced in the global marketplace. All large capital expenditures required are now complete.
GMP Compliant & Ready To Ship
MDMA 40mg & 60mg and 5mg Natural Psilocybin Extract GMP Capsules are ready to be shipped on demand to any licensed entity able to accept controlled substances through Optimi's GMP compliant Drug Establishment License.
The Rescheduling of MDMA Psilocybin, or any other psychedelic compound presents a unique opportunity for Optimi to gain market share immediately while the competition is still in time consuming clinical development phase.
OPTIMI HEALTH CORP
CSE: OPTI
OTCQX: OPTHF
FSE: 8BN
“Our participation in the placement speaks to our belief that the Company can achieve its plan to be a world leader in psychedelic product development and global distribution.”
Chip Wilson, Founder of Lululemon
OPTIMI HEALTH CORP
CSE: OPTI
OTCQX: OPTHF
FSE: 8BN
Get Instant Access. No commitment required.
OPTIMI HEALTH CORP
CSE: OPTI
OTCQX: OPTHF
FSE: 8BN
1. Download Our Investor Presentation
Get immediate access to Optimi Health’s investor presentation and discover how we’re transforming mental health through cutting-edge psychedelic therapies.
2. Receive Monthly Industry Updates
Stay ahead with monthly insights on the latest psychedelic advancements and Optimi Health’s progress—right to your inbox.
3. Join Live Investor Webinars
Connect with experts, ask questions, and explore the future of psychedelic mental health treatments in our live investor webinars.
OPTIMI HEALTH CORP
CSE: OPTI
OTCQX: OPTHF
FSE: 8BN
CEO
Bill Ciprick
At Optimi Health, we’re driven by a simple yet profound mission: to harness the power of psychedelics to transform mental health care.
Our state-of-the-art facility in Princeton, British Columbia, stands as one of the largest psychedelic mushroom farms in the world, producing psilocybin and MDMA for therapeutic use.
With +CA$30 million in investments and extensive regulatory approvals, we’re leading the charge in providing natural, high-quality psychedelics to psychiatrists and clinics globally.
We believe that our naturally derived psilocybin offers more therapeutic benefits than lab-synthesized alternatives, which is why we’ve prioritized quality and innovation in every step of our cultivation process.
As the psychedelic market rapidly expands, from current value of US$2.9 billion in 2023 to US$6.8 billion by 2027, Optimi Health is poised for significant growth.
We’re committed to delivering life-changing therapies that go beyond traditional pharmaceuticals, offering patients real relief and hope.
Thank you for your support.
Together, we’re not just building a company—we’re shaping the future of mental health.
"Australian psychiatrists can now prescribe Optimi's MDMA and Psilocybin capsules for theraputic use in patients. To have both of these GMP drugs in market is a very humbling achievement."
JJ Wilson, Chairman of the Board
Download our FREE No-Obligation Investor Presentation and discover how Optimi Health is leading the charge in the psychedelic revolution.
OPTIMI HEALTH CORP
CSE: OPTI
OTCQX: OPTHF
FSE: 8BN
Legal Disclaimer
1. General Information and Liability
This landing page is provided and maintained by Fairfax Partners Inc. ("Fairfax") exclusively for informational purposes related to Optimi Health Inc. ("Optimi"). Fairfax assumes no responsibility for the accuracy, completeness, or timeliness of any information provided on this page. The content herein is composed of public, non-material information that has been obtained from sources deemed reliable but is not guaranteed by Fairfax as to its accuracy or completeness.
2. No Endorsement or Financial Advice
Fairfax does not own shares or any other financial interests in Optimi Health Inc. Fairfax's role is strictly limited to the creation and maintenance of this landing page. Fairfax does not provide, endorse, or imply any form of financial, legal, or investment advice, nor does it recommend or endorse the purchase or sale of any securities or financial instruments related to Optimi Health Inc. or any other entity. Fairfax was compensated C$43,600 by Optimi Health Inc. for its services in setting up and maintaining this landing page.
3. Risk Disclaimer
Investing in securities, including those of Optimi Health Inc., inherently involves risks, including the potential loss of principal. Fairfax and Optimi Health Inc. expressly disclaim any liability for any direct, indirect, consequential, or incidental damages or losses incurred by any party arising from the use or reliance on the information presented on this page.
4. Forward-Looking Statements
This webpage contains forward-looking statements within the meaning of Canadian securities laws. These statements reflect Optimi Health Inc.'s current expectations and views about future events. Forward-looking statements are not historical facts; they often include terms like "expects," "anticipates," "plans," "believes," and similar phrases that indicate expectations of future outcomes. These statements involve risks, assumptions, and uncertainties that could cause actual results to differ significantly from those expressed or implied. No assurance can be given that these expectations will prove accurate.
Optimi Health Inc.'s forward-looking statements relate to its activities under its Health Canada dealer's license, including business operations involving Psilocybin, Psilocin, and other psychedelic substances. These statements are based on several assumptions and are subject to risks beyond Optimi Health Inc.'s control, including but not limited to, the impact of the COVID-19 pandemic. More details can be found in the "Forward-Looking Statements" and "Risk Factors" sections of Optimi Health Inc.'s Annual Information Form dated January 30, 2024, available at www.sedar.com.
Optimi Health Inc. does not undertake any obligation to update these forward-looking statements, except as required by law. New risks and uncertainties may emerge, and it is not possible to predict all of them or their potential impacts. Please consider this cautionary statement when reviewing forward-looking information on this webpage.
5. Due Diligence and Professional Advice
All visitors to this landing page are strongly encouraged to perform their own comprehensive due diligence before making any investment decisions. This includes, but is not limited to, reviewing publicly available financial statements, reports, and other relevant documents related to Optimi Health Inc., or consulting with independent, qualified financial advisors or legal professionals who can provide tailored advice based on individual circumstances.
6. No Offer or Solicitation
Nothing on this page constitutes an offer to sell or a solicitation to buy any securities or financial instruments. Any investment decision made by a visitor is solely the responsibility of the individual and should be based on their own analysis and judgment. The information on this page should not be considered a substitute for professional investment advice.
7. Limitation of Fairfax’s Role and Responsibilities
Fairfax’s involvement with this landing page is limited to providing a platform for information dissemination as directed by Optimi Health Inc. Fairfax has no control over, and assumes no responsibility for, the content provided by Optimi Health Inc. or any actions taken by visitors based on such content. Fairfax is not liable for any errors, omissions, or inaccuracies in the content provided, nor for any actions taken based on the information on this page.
8. Acknowledgment and Agreement
By accessing or using this landing page, you acknowledge that you have read, understood, and agreed to be bound by this legal disclaimer. You also acknowledge and accept that any reliance on the information contained on this page is at your own risk.